期刊文献+

肿瘤组织中的CYP1B1及其抑制剂的抗肿瘤活性 被引量:2

Tumor Cytochrome P450 1B1 and Antitumor Activities of Its Inhibitors
下载PDF
导出
摘要 综述细胞色素P450酶(CYP)1B1在肿瘤组织中的表达、在肿瘤的发生发展和诊断与干预中的作用以及其抑制剂的研发和抗肿瘤活性。CYP1B1在正常组织中低表达,而在许多肿瘤组织中则特异性高表达,可激活和代谢产生致癌物质,并可致多种抗癌药物代谢失活而使肿瘤耐药,因此它既可用于早期癌症的诊断,又可作为理想的抗肿瘤作用靶点而用于药物研发。 The tumor-specific expression, function in tumor development and role in tumor diagnosis and interference of CYP1 B1 and the development and antitumor activities of its inhibitors were reviewed. CYP1 B1, which is expressed highly in many tumors but lowly in normal tissues, could induce carcinogens to be produced via activation and metabolism and cause metabolic inactivation of many anticancer drugs to lead to tumor drug-resistance. It may play the important roles in tumor diagnosis and drug development as a promising antitumor target.
作者 张明 柳晓泉
出处 《药学进展》 CAS 2009年第4期157-162,共6页 Progress in Pharmaceutical Sciences
关键词 细胞色素P450酶1B1 肿瘤 雌激素代谢 前致癌物激活 抑制剂 抗肿瘤活性 CYP1 B1 tumor estrogen metabolism proearcinogen activation inhibitor antitumor activity
  • 相关文献

参考文献26

  • 1Bruno R D, Njar V C. Targeting eytoehrome P450 enzymes :a new approach in anticaneer drug development [ J]. Bioorg Med Chem ,2007,15 ( 15 ) :5047-5060.
  • 2Chun Y J, Kim S. Discovery of cytochrome Pd50 1B1 inhibitors as new promising anti-cancer agents [ J ]. Med Res Rev,2003,23(6) :657-668.
  • 3Patterson L H, Murray G I. Tumour cytochrome P450 and drug activation [ J ]. Curr Pharm Des, 2002, 8 ( 15 ) : 1335-1347.
  • 4McFadyen M C, McLeod H L, Jackson F C, et al. Cyto- chrome P450 CYP1 B1 protein expression:a novel mecha- nism of anticancer drug resistance [ J ]. Biochem Pharmacol,2001,62(2) :207-212.
  • 5Cavalieri EL, Stack D E, Devanesan P D, et al. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators[ J]. Proc Nail Acad Sci USA, 1997,94 (20) : 10937-10942.
  • 6Dawling S, Roodi N, Parl F F. Methoxyestrogens exert feed back inhibition on eytochrome P4501A1 and 1B1 [J]. Cancer Res ,2003,63 (12) :3127-3132.
  • 7Saaski K,Tanaka Y,Kaneuehi M,et al. CYP1B1 gene poly- morphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor a andestrogen receptor b expressions [ J ]. Cancer Res, 2003,63 ( 14 ) : 3913-3918.
  • 8AkliUu E, Oscarson M, Hidestrand M, et al. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population[J]. Mol Pharmacol,2002,61 (3) :586-594.
  • 9Zheng W, Xie D W, Jin F, et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer [ J ]. Cancer Epidemiol Biomarkers Prey ,2000,9(2) : 147-150.
  • 10Kocabas N A, Sardas S, Cholerton S, et al. Cytochrome P450 CYP1B1 and cateehol O-methyltransferase(COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population [ J ]. Arch Toxicol, 2002,76 ( 11 ) : 643-649.

同被引文献58

  • 1Dong N,Yu J, Wang C,et al. Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer trea- ted with docetaxel plus capecitabine [ J ]. J Cancer Res Clin Onco1,2012,138 (7) : 1197-1203.
  • 2Van Erp NP, Eechoute K,van der Veldt AA,et al. Pharmaco- genetic pathway analysis for determination of sunitinib-in-duced toxicity[J]. J Clin 0ncot,2009,27(26) :4406-4412.
  • 3Nie Q,Yang XN,An SJ,et al. CYP1A1 *2A polymorphism as a predictor of clinical outcome in advanced lung cancer pa- tients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism [ J ]. Eur J Cancer, 2011,47 (13) : 1962-1970.
  • 4Laroche-Clary A, Le Morvan V, Yamori T, et al. Cytochrome P450 1 B1 gene polymorphisms as predictors of anticancer drug activity: sudies with in vitro models [ J ]. Mol Cancer Ther', 2010,9(12) :3315-3321.
  • 5Pastira I, Giovannetti E ,Chioni A ,et al. Cytochrome 450 1 B1 (CYP1B1) potymorphisms associated with response to do- cetaxel in Castration-Resistant Prostate Cancer (CRPC) pa- tients [ J ]. BMC Cancer,2010,10:511.
  • 6Rizza R,-Spaggiari F,hadelli M,et al. Association of CYP1B1 with hypersensitivity iodueed by taxane therapy in breast eancer patients [ J ]. Breast Cancer Res Treat, 2010,124 ( 2 ) : 593-598.
  • 7Park SR,Kong SY,Nam BH,et al. CYP2A6 and ERCC1 pol- ymorphisms correlate with efficacy of S-! plus eisplatin in me- tastatic gastric cancer patients [ J] . Br J Cancer, 2011,104 (7) :1126-1134.
  • 8Kong SY, Lira HS, Nam BH, et al. Association of CYP2A6 polymorphisms with S-1 plus dQcetaxel therapy outcomes in metastatic gastric cancer [ J ]. Pharmacogenomics, 2009, 10 (7) :1147-1155.
  • 9Xie HJ, Yasar U, Lundgren S, et al. Role of polymorp!aic hu- man CYP2B6 in cyclophosphamide bioactivation [ J ]. Phar- rnacogenomies , 2003,3:53-61.
  • 10Xie HJ, Griskevicius L, Stgthle L, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies [ J ]. Eur J Pharm Sci, 2006,27 : 54-61.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部